Chinese biotech firm Ascletis said to raise $400m in HK IPO

Ascletis Pharma

Chinese biotech Ascletis Pharma Inc raised $400 million after pricing its initial public offering (IPO) in the middle of an indicative range, three sources said, in the first such Hong Kong listing under new rules designed to attract early-stage biotech firms.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.